---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-193424"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:17:59.434295+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Aligos shareholders elect three Class III directors and ratify Ernst & Young as auditor at 2023 Annual Meeting

## Summary
- Jack B. Nielsen (20,201,692 For), Bridget Martell (24,022,757 For), and Carole Nuechterlein (21,653,372 For) elected as Class III directors with 9,713,860 broker non-votes.
- Ernst & Young ratified as independent auditor for FY2023: 34,670,204 For, 11,096 Against, 918 Abstain.
- As of record date May 23, 2023, 40,410,244 shares were outstanding and entitled to vote.

## SEC filing metadata
- accession: 0001193125-23-193424
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312523193424/0001193125-23-193424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312523193424/d428056d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-193424
- JSON: https://secwatch.observer/filing/0001193125-23-193424.json
- Plain text: https://secwatch.observer/filing/0001193125-23-193424.txt

## Key facts
- Shareholder Votes
  Aligos Therapeutics, Inc. shareholders approved Ratification of the selection by the audit committee of the board of directors of the Company of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. at the 2023-07-20 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-07-20
  source text: Proposal 2 . The ratification of the selection by the audit committee of the board of directors of the Company of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. The results of the vote were as follows: Votes For Votes Against Abstentions 34,670,204 11,096 918
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000119312523193424/0001193125-23-193424-index.htm
- Shareholder Votes
  Aligos Therapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected. at the 2023-07-20 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-07-20
  source text: Proposal 1 . The election of three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Jack B. Nielsen 20,201,692 4,766,666 9,713,860 Bridget Martell, M.A., M.D. 24,022,757 945,601 9,713,860 Carole Nuechterlein, J.D. 21,653,372 3,314,986 9,713,860
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000119312523193424/0001193125-23-193424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.